Betahistine hydrochloride is an orally administered antihistaminic drug. It has a very strong affinity for histamine H3 receptors and a weak affinity for histamine H1 receptors. It has been used to control vertigo in patients of Meniere’s disease with half-life of 2-3 hrs. The purpose of this research was to develop a novel gastro retentive drug delivery system based on direct compression method for sustained delivery of active agent to improve the bioavailability, reduce the number of doses and to increase patient compliance. Gastro retentive floating tablets of betahistine HCl were prepared by direct compression method using altered concentrations of HPMC K4, HPMC K15 and PVK30 as polymers. Then all the nine formulations were evaluated for uniformity of weight, hardness, thickness, friability test, floating lag time, drug content, dissolution studies and drug release studies. Compatibility studies was execution during FTIR shown that there was absence of probable chemical interaction between pure drug and excipients. The varying concentration of gas generating agent and polymers was found to effect on in-vitro drug release and floating lag time. In-vitro drug release of floating gastro retentive tablet of lovastatin shown that the formulation F6 was found to be the best formulation F6 as it showed less friability< 1, good hardness 4.9 kg/cm2, less floating lag time 2.5 (sec). The results indicated that optimizes formulation F6 on immersion in 0.1N HCl at 37±0.5°C tablets immediately and remain buoyant upto 12hr without disintegration. Thus, it can be concluded that prepared floating tablets of betahistine HCl may prove to be a potential candidate for safe and effective controlled drug delivery over an extended period of time for gastro retentive drug delivery system.
Loading....